Background: Cytoreductive surgery (CRS) roles in advanced EC are not fully defined and there are few published data about role of neoadjuvant chemotherapy followed by cytoreductive surgery in advanced endometrioid endometrial adenocarcinoma which is the commonest histopathological subtype of EC. Objective: The aim of the study was to evaluate the roles of neoadjuvant chemotherapy followed by interval cyto-reductive surgery in reducing progression improving survival and prognosis of patients who were initially diagnosed with advanced stage EC. Patients and Methods: we collected 50 patients of advanced endometrial carcinoma stage III and divided them into 2 groups the first group included 36 (72%) patients who underwent cytoreductive surgery after neoadjuvant chemotherapy and remaining patients who have not undergone surgery. Results: Patients who underwent interval cytoreductive surgery after neoadjuvant chemotherapy had longer progression-free survival rate (12.53 vs. 5 months, p = 0.001) and longer overall survival rate (25 vs. 8 months, p = 0.002) in comparison with patients who have not undergone surgery. Conclusions: Using neo-adjuvant chemotherapeutic agents followed by cyto-reductive surgery in cases of advanced endometrial carcinoma reduces rates of disease recurrences and improving patients' survival rates.